Table 3.
Basic clinical characteristics between the enrolled subjects and excluded subjects when starting the second cohort of PHASE study (Parkinson's disease and the relationships with circadian biological rhythms and sleep).
| total patients | enrolled 22 PD patients | excluded 19 PD patients | p | |
|---|---|---|---|---|
| age | 70.5 ± 7.5 | 68.0 ± 7.4 | 73.4 ± 6.7 | 0.049 |
| men | 20 | 11 | 9 | 1 |
| disease duration (months), median (IQR) | 51 (11, 262) | 54 (11, 241) | 50 (11, 262) | 0.548 |
| H-Y staging | 2.2 ± 1.1 | 2.0 ± 0.9 | 2.6 ± 1.1 | 0.051 |
| UPDRS part 1 item 2 (hallucination) | 9 | 3 | 6 | 0.26 |
| UPDRS part 3, median (IQR) | 18 (5, 86) | 16 (5, 49) | 21 (6, 86) | 0.44 |
| UPDRS part 4, median (IQR) | 0.7 (0, 24) | 0.9 (0, 14) | 0.5 (0, 24) | 0.326 |
| wearing-off * | 13 | 8 | 5 | 0.524 |
| dyskinesia* | 3 | 2 | 1 | 1 |
| Depression, median (IQR) | 5.9 (0, 14) | 5.00 (0, 14) | 6.67 (1, 14) | 0.16 |
| Depression scale ≧6, n (%) | 23 | 10 | 13 | 0.209 |
| Apathy, median (IQR) | 16.4 (5, 30) | 14.8 (5, 25) | 17.6 (10, 30) | 0.079 |
| Apathy scale ≧16, n (%) | 23 | 9 | 14 | 0.058 |
| Fatigue, median (IQR) | 33.5 (0, 63) | 31.5 (0, 63) | 35.3 (0, 59) | 0.979 |
| Fatigue scale ≧3.3, n (%) | 8 | 6 | 2 | 0.249 |
| RBD, median (IQR) | 4.1 (1, 13) | 4.5 (1, 10) | 3.5 (1, 13) | 0.469 |
| RBD scale ≧5, n (%) | 18 | 11 | 7 | 0.531 |
| MMSE | 27.3 ± 3.2 | 28.8 ± 1.3 | 25.5 ± 3.8 | <0.001 |
| PSQI | 6.2 ± 3.5 | 5.8 ± 3.4 | 6.7 ± 3.6 | 0.331 |
| medications | ||||
| levodopa dosage | 245.1 ± 143.5 | 213.6 ± 145.7 | 281.5 ± 135.6 | 0.075 |
| dopamine agonist use | 16 | 9 | 7 | 1 |
| COMT inhibitor use | 3 | 2 | 1 | 1 |
| MAO-B inhibitor use | 11 | 7 | 4 | 0.499 |
| history of depression | 4 | 3 | 1 | 0.607 |
| anti-depressant drug use | 4 | 2 | 2 | 1 |
HY: Hoehn Yahr stage, UPDRS: Unified Parkinson's disease Rating Scale, MMSE: Mini Mental State Examination, RBD: rapid eye movement (REM) sleep behavior disorder, * on URDRS part 4.